MehdiShahidiMD

Pulmonology • Springfield, IL

Critical Care Medicine, Pleural Disease

Physician

Join to view full profile

Dr. Shahidi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Shahidi's full profile

Already have an account?

Office
800 E Carpenter St
Springfield, IL 62769
Phone+1 217-528-7541

Education & Training

Southern Illinois UniversityFellowship, Pulmonary Disease and Critical Care Medicine, 2012 - 2014
Southern Illinois UniversityResidency, Internal Medicine, 2009 - 2012
Istanbul University FomClass of 2006

Certifications & Licensure

IL State Medical License 2009 - 2026
MO State Medical License 2017 - 2025
CA State Medical License 2013 - 2023
NY State Medical License 2016 - 2021
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Critical Care Medicine
American Board of Internal Medicine Pulmonary Disease

Publications & Presentations

PubMed

278 citations
Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors
Timothy A. Yap, Laura Vidal, Jan Adam, Peter Stephens, James Spicer
Journal of Clinical Oncology. 2010-09-01
269 citations
LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both
Nobuyuki Katakami, Shinji Atagi, Koichi Goto, Toyoaki Hida, Takeshi Horai
Journal of Clinical Oncology. 2013-09-20
2453 citations
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Lecia V. Sequist, James Chih-Hsin Yang, Nobuyuki Yamamoto, Kenneth J. O'Byrne, Vera Hirsh
Journal of Clinical Oncology. 2013-09-20

Press Mentions

New Data Showed OFEV® (Nintedanib) Slows Decline of Lung Function in Broad Range of Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype(1)November 27th, 2019
Ofev Reduces Lung Function Decline in Patients with Fibrotic Lung Diseases, Phase 3 Trial ShowsOctober 2nd, 2019
INBUILD® Meets Primary Endpoint - Study Evaluated Nintedanib in Patients Across a Range of Progressive Fibrosing Interstitial Lung diseases1September 30th, 2019
Join now to see all